Indica Labs and Paige announce partnership to enhance AI integration in anatomic pathology
In a move set to advance the field of computational pathology, Indica Labs and Paige have announced a strategic partnership aimed at integrating Paige’s diagnostic AI models into Indica’s HALO AP workflow management software. The collaboration promises to deliver AI-enabled workflows that could significantly improve laboratory efficiency, diagnostic quality, and patient outcomes in anatomic pathology.
The partnership will see Paige’s pan-cancer
AI application, developed using their proprietary foundation model technology, seamlessly integrated into Indica’s HALO AP platform. This integration will allow pathologists to execute Paige’s AI applications and view results directly within the HALO AP image management system, streamlining
the diagnostic process.
Peter Hamilton, GM of Diagnostics at Paige, commented: “We are excited to work with Indica Labs to make Paige’s powerful AI capabilities available to customers through the HALO AP platform. We are confident that integrating the technologies that Indica and Paige have developed will provide pathologists with the richest set of capabilities that will drive improvements in cancer diagnostics.”
The partnership extends beyond mere software integration. Both companies have committed to coordinating their commercial efforts to provide comprehensive solutions for new and existing customers. This approach aims to ensure that all integrated products maintain the highest standards of quality from technical, product support, and regulatory perspectives.
Steven Hashagen, CEO of Indica Labs, highlighted the significance of this collaboration: “This partnership represents a significant step forward in our commitment to delivering innovative solutions that meet the evolving needs of our customers. Paige has been a pioneer in AI for pathology diagnostics, so bringing their tools onto our platform is an exciting opportunity for us and our customers.”
Future developments
While the initial focus of this partnership is on clinical diagnostics, both companies have expressed intentions to expand their collaborative efforts into other areas, including pharmaceutical services, preclinical, and translational applications. The integration is expected to roll out within the next few months, with parallel efforts in the life science segment to follow.
This partnership comes at a time when the field of digital pathology is rapidly evolving. The integration of AI technologies into pathology workflows has the potential to significantly enhance the accuracy and efficiency of cancer diagnosis. By combining Indica Labs’ expertise in computational pathology software with Paige’s advanced AI models, this collaboration could set new standards in digital pathology and cancer diagnostics.
Broader impact on cancer research and treatment
The partnership between Indica Labs and Paige represents a significant step forward in the application of AI to cancer diagnosis and research. By leveraging Paige’s access to extensive pathology data from Memorial Sloan Kettering Cancer Center, the collaboration has the potential to create more comprehensive and diverse AI solutions for cancer detection, diagnosis, and treatment.
